faricimab (Vabysmo)

following a full submission:

faricimab (Vabysmo®) is accepted for restricted use within NHSScotland.

Indication under review: For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO).

SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) of 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.

In two phase III studies faricimab was non-inferior to an anti-vascular endothelial growth factor treatment for change in BCVA from baseline at 1 year.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.